Castle Biosciences, Inc. (CSTL)
NASDAQ (NMS) NASDAQ (NMS) Primary 
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests.
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 50.8% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock
Castle Biosciences (CSTL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Castle Biosciences (CSTL) Upgraded to Buy: Here's Why
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet
The mean of analysts' price targets for Castle Biosciences (CSTL) points to a 51.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now
Buy these four top-ranked stocks, CSTL, OPFI, GCT and QIFU, with solid net profit margins to enhance your portfolio returns.
4 Solid Net Profit Margin Stocks to Boost Portfolio Returns
Here, we present four stocks, CSTL, QFIN, ESEA and STRA, with solid net profit margins that can contribute toward making a strong portfolio.
Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 42% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Castle Biosciences (CSTL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Corey Rosenbaum - Scotiabank Thomas Flaten - Lake Street Mason Carrico - Stevens Puneet Souda - Leerink Partners Paul Knight - KeyBanc Operator Good afternoon, and welcome to Castle Biosciences Third Quarter 2024 Conference Call. As a reminder, today's call is being recorded.
